EYPT
EYEPOINT Details LUGANO Miss, Says Nine Patients Drove Failed Endpoint
Expanded Phase 3 data show DURAVYU missed non-inferiority in wet AMD overall but hit it when an asymmetric cohort of nine patients is excluded.
EYPT
Market-moving news on EyePoint Pharmaceuticals (NASDAQ: EYPT): filings, earnings, deals and other events, from REDFILED.